{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:42:05Z","timestamp":1788900125328,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR065873"],"award-info":[{"award-number":["R01AR065873"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.omtm.2019.11.020","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T21:24:59Z","timestamp":1575581099000},"page":"133-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Comparisons of Infant and Adult Mice Reveal Age Effects for Liver Depot Gene Therapy in Pompe Disease"],"prefix":"10.1016","volume":"17","author":[{"given":"Sang-oh","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Arnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Everitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai K.","family":"ElMallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight D.","family":"Koeberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2019.11.020_bib1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/mt.2008.72","article-title":"Gene delivery to the juvenile mouse liver using AAV2\/8 vectors","volume":"16","author":"Cunningham","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib2","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/mt.2009.88","article-title":"AAV2\/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice","volume":"17","author":"Cunningham","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib3","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/mt.2011.151","article-title":"AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta)","volume":"19","author":"Wang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib4","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/mt.2012.129","article-title":"Long-term survival of the juvenile lethal arginase-deficient mouse with AAV gene therapy","volume":"20","author":"Lee","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib5","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.11.020_bib6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/mt.2010.257","article-title":"Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer","volume":"19","author":"Cotugno","year":"2011","journal-title":"Mol. Ther."},{"issue":"R1","key":"10.1016\/j.omtm.2019.11.020_bib7","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1093\/hmg\/ddz133","article-title":"Gene therapy for glycogen storage diseases","volume":"28","author":"Kishnani","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2019.11.020_bib8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib9","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/sj.gt.3302550","article-title":"Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors","volume":"12","author":"Mah","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.mt.6300100","article-title":"Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors","volume":"15","author":"Mah","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.omtm.2018.11.002","article-title":"AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice","volume":"12","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2019.11.020_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/atm.2019.05.02","article-title":"Liver depot gene therapy for Pompe disease","volume":"7","author":"Kishnani","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.omtm.2019.11.020_bib13","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ymthe.2005.01.012","article-title":"Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter","volume":"11","author":"Sun","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib15","series-title":"Glycogen Storage Disease Type II: Acid \u221d-Glucosidase (Acid Maltase) Deficiency","first-page":"3389","article-title":"The Metabolic and Molecular Basis for Inherited Disease","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.omtm.2019.11.020_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction","volume":"4","author":"Han","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2019.11.020_bib17","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ymthe.2018.06.023","article-title":"Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I\/II Clinical Trial of Clenbuterol in Pompe Disease","volume":"26","author":"Koeberl","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ymgme.2015.09.012","article-title":"A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease","volume":"117","author":"Han","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2019.11.020_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/hum.2018.016","article-title":"Systemic delivery of AAVB1-GAA clears glycogen and prolongs survival in a mouse model of Pompe Disease","volume":"30","author":"Keeler","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib20","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2019.11.020_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymthe.2004.10.004","article-title":"Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II","volume":"11","author":"Sun","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2002-09-2889","article-title":"Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway","volume":"102","author":"Davidoff","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2019.11.020_bib23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jgm.1372","article-title":"Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression","volume":"11","author":"Sun","year":"2009","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2019.11.020_bib24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/GIM.0b013e3181a87867","article-title":"Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker","volume":"11","author":"Young","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2019.11.020_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1566523219666190621113807","article-title":"Reduction of Autophagic accumulation in Pompe disease mouse model following gene therapy","volume":"19","author":"McCall","year":"2019","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.omtm.2019.01.006","article-title":"Intravenous Injection of an AAV-PHP.B vector encoding human acid \u03b1-glucosidase rescues both muscle and CNS defects in murine Pompe disease","volume":"12","author":"Lim","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2019.11.020_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib28","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1089\/hum.2011.063","article-title":"Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease","volume":"23","author":"Zhang","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/hum.2015.103","article-title":"Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease","volume":"27","author":"Doerfler","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2019.11.020_bib31","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/mt.2008.133","article-title":"Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy","volume":"16","author":"Sun","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1096\/fj.12-207472","article-title":"Adjunctive \u03b22-agonists reverse neuromuscular involvement in murine Pompe disease","volume":"27","author":"Li","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.omtm.2019.11.020_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2016.03.006","article-title":"Salmeterol enhances the cardiac response to gene therapy in Pompe disease","volume":"118","author":"Han","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2019.11.020_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/hum.2018.197","article-title":"Salmeterol with liver depot gene therapy enhances the skeletal muscle response in murine Pompe disease","volume":"30","author":"Han","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib35","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1089\/hum.2015.033","article-title":"Synergistic efficacy from gene therapy with coreceptor blockade and a \u03b22-agonist in murine Pompe disease","volume":"26","author":"Han","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/hum.2014.115","article-title":"Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade","volume":"26","author":"Han","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib37","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2006.08.001","article-title":"Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II","volume":"14","author":"Sun","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2019.11.020_bib39","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.11.020_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.020_bib41","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2019.11.020_bib42","first-page":"621","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtm.2019.11.020_bib43","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2019.11.020_bib44","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:31:01Z","timestamp":1762421461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050119301457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":44,"alternative-id":["S2329050119301457"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2019.11.020","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparisons of Infant and Adult Mice Reveal Age Effects for Liver Depot Gene Therapy in Pompe Disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2019.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors.","name":"copyright","label":"Copyright"}]}}